DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Clinical Trials
579
Trial Phases
6 Phases
Drug Approvals
9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (537 trials with phase data)• Click on a phase to view related trials
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
- Conditions
- Primary HypercholesterolaemiaMixed Dyslipidemia
- Interventions
- Drug: Combination of bempedoic acid and ezetimibe
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2560
- Registration Number
- NCT07206472
Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 58
- Registration Number
- NCT07201545
- Locations
- 🇵🇹
Research Site, Porto, Portugal
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
- Conditions
- Advanced or Metastatic Adrenocortical CarcinomaMetastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: DS9051b
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT07189403
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 58
- Registration Number
- NCT07182383
- Locations
- 🇵🇹
Research Site, Porto, Portugal
A Study of DS5361b in Participants With Advanced Solid Tumors
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 192
- Registration Number
- NCT07182591
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 62
- Next
News
Marengo Therapeutics Advances Phase 2 Expansion of Invikafusp Alfa-Trodelvy Combination for Metastatic Breast Cancer
Marengo Therapeutics has completed the Phase 1b safety run-in of its STARt-002 trial and determined the recommended Phase 2 dose for invikafusp alfa combined with Trodelvy in metastatic breast cancer patients.
Immuto Scientific Secures $8M Funding and Daiichi Sankyo Partnership to Advance AI-Driven Cancer Target Discovery
Immuto Scientific closed an oversubscribed $8 million Seed 2 financing round led by DYDX to advance its AI-enabled structural surfaceomics platform for drug discovery.
Hengrui Medicine Receives China's First EZH2 Inhibitor Approval for Hematological Malignancies
Hengrui Medicine's Zemetostat received conditional approval from China's NMPA, becoming the country's first EZH2 inhibitor for treating relapsed or refractory peripheral T-cell lymphoma.
Daiichi Sankyo Initiates Development of Triple-Combination Lipid-Lowering Tablet to Address Treatment Gaps
Daiichi Sankyo Europe announced the initiation of development for new oral triple combination tablets containing bempedoic acid, ezetimibe, and different doses of statins (atorvastatin or rosuvastatin) to improve LDL-C management and treatment adherence.
Gastric Cancer Pipeline Shows Robust Growth with 220+ Therapies in Development Across 200+ Companies
DelveInsight's 2025 pipeline report reveals over 200 companies developing 220+ therapeutic candidates for gastric cancer treatment across all clinical stages.
I-Mab Strengthens Leadership Team with Three New Board Appointments and R&D Committee Formation
I-Mab appointed three seasoned biotech executives to key leadership positions, including Dr. Robert Lenz and Ms. Xin Liu to the Board of Directors and Dr. Ken Takeshita to the Scientific Advisory Board.
GIST Treatment Pipeline Shows Robust Activity with 28+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 pipeline analysis reveals 25+ companies developing 28+ therapies for gastrointestinal stromal tumors, indicating strong industry investment in this rare cancer space.
Merck's Ifinatamab Deruxtecan Receives FDA Breakthrough Designation for Small Cell Lung Cancer
Merck and Daiichi Sankyo's ifinatamab deruxtecan received FDA Breakthrough Therapy Designation for extensive-stage small cell lung cancer patients who progressed after platinum-based chemotherapy.
FDA Maintains Record-Breaking Approval Pace Despite Organizational Upheaval, Highlighting Three Breakthrough Therapies
The FDA has approved 84 drugs in 2025 so far, marking the second-highest total for this period despite major organizational changes including 3,500 staff layoffs.
HER2-Positive Gastric Cancer Pipeline Shows Robust Activity with 20+ Companies Developing Novel Therapies
DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.